Block listing Interim Review

Summary by AI ^BETAClose X

Advanced Medical Solutions Group plc has provided an update on its block admission arrangements for various share schemes, including the Employee Share Purchase Plan, Group Share Option Plan, and others. Between September 6, 2025, and March 5, 2026, the company increased its block schemes by a total of 10,400,000 ordinary shares, while issuing 1,856,229 shares under these schemes. The remaining unallotted securities across all schemes at the end of the period total 6,502,313 ordinary shares. The company also noted the original listing of 4,476,264 ordinary shares on September 6, 2018, and an additional 10,400,000 ordinary shares on September 15, 2025.

Disclaimer*

Advanced Medical Solutions Grp PLC

06 March 2026

6 March 2026

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:		Advanced Medical Solutions Group plc
Name of scheme:		Block Scheme for: 1. Employee Share Purchase Plan 2. Group Share Option Plan 3. Company Share Option Plan 4. Unapproved Executive Share Option Scheme 5. Long Term Incentive Plan 6. Deferred Annual Bonus Scheme
Period of return:	From:	6 September 2025	To:	5 March 2026
Balance of unallotted securities under scheme(s) from previous return:		1. Nil 2. Nil 3. 87,573 4. 84,541 5. Nil 6. 229,762
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1. 2,000,000 2. 4,000,000 3. 200,000 4. 200,000 5. 4,000,000 6. Nil
Less: Number of securities issued/allotted under scheme(s) during period:		1. 563,881 2. 20,481 3. 32,502 4. 37,057 5. 758,428 6. 11,919
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1. 1,436,119 2. 3,979,519 3. 255,071 4. 247,484 5. 3,241,572 6. 217,843
Number and class of securities originally listed and the date of admission:		(i) 4,476,264 ordinary shares of 5p each admitted on 6 September 2018. (ii) 10,400,000 ordinary share of 5p each admitted on 15 September 2025.

Name of contact:	Owen Bromley
Telephone number of contact:	01606 545514

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations

Optimum Strategic Communications	Tel: +44 (0) 20 4566 8543
Mary Clark / Nick Bastin / Isabelle Abdou	AMS@optimumcomms.com

Investec Bank PLC (NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson

Berenberg (Joint Broker)	Tel: +44 (0) 20 3207 7800
Toby Flaux / Detlir Elezi

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is an innovative tissue healing medical device company delivering high-performing solutions that match or surpass market leaders, clinically, technically, and commercially. From adhesives and sealants, to biosurgical devices and sutures, AMS's products offer superior usability, quality and design. AMS's strength lies in combining advanced material science with applicator device design and development, in collaboration with surgeons and Key Opinion Leaders, creating differentiated devices that improve patient outcomes without compromising quality or affordability.

AMS's scalable, resilient business model is built on disciplined execution, portfolio focus, and capital efficiency. Its diversified product and geographic mix mitigates volatility, ensuring consistent performance even when individual segments fluctuate. Following its acquisition of Peters Surgical, AMS is unlocking operational and commercial synergies, accelerating its U.S. and international expansion, and increasing the percentage of sales made through its direct sales teams. With surgical products driving the lion's share of group revenues and a clear top-line trajectory, AMS is positioned for scalable growth, margin improvement, and long-term value creation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END